MAPT and Alzheimer disease: Recent advancements, such as the development of aptamer–antibody sandwich biosensors, have enabled the detection of tau381 at concentrations as low as 0.42 pM (significantly lower than healthy population plasma tau concentration [~15.6 pg/mL]) [62], showcasing the potential for early AD detection [59].